Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
The British Journal of Ophthalmology|June 19, 2003
Digital analysis of choroidal neovascularisation in consecutive fluorescein angiograms for use in longitudinal clinical trialsC Bellmann, D W Miller, K Mehltretter, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 25, 2013
Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACHY Poulin, J J Crowley, R G Langley, et al.Anaesthesia|January 17, 2004
Acupuncture compared to placebo-acupuncture for postoperative nausea and vomiting prophylaxis: a randomised placebo-controlled patient and observer blind trialK Streitberger, M Diefenbacher, A Bauer, et al.Journal of the American College of Cardiology|March 27, 2001
Prognostic value of Doppler echocardiographic mitral inflow patterns: implications for risk stratification in patients with chronic congestive heart failureA Hansen, M Haass, C Zugck, et al.The British Journal of Dermatology|May 15, 2021
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trialD Thaçi, K Eyerich, A Pinter, et al.Neuropediatrics|November 9, 2000
Nonconvulsive status epilepticus--a possible cause of mental retardation in patients with Lennox-Gastaut syndromeM Hoffmann-Riem, W Diener, C Benninger, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2021
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trialD Thaçi, A M Soliman, K Eyerich, et al.The British Journal of Dermatology|December 1, 2007
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)J-H Saurat, G Stingl, L Dubertret, et al.Rheumatology (Oxford, England)|May 17, 2007
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practiceS Bombardieri, A A Ruiz, P Fardellone, et al.Pageof 3